Celltrion Accelerates Antibody, Kit Development As It Takes Coronavirus Initiative
Urges Other Large Firms To Join Effort
Executive Summary
Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.
You may also be interested in...
Celltrion Antibody Becomes First Home-Grown COVID-19 Drug Approval In Korea
Helped by government support for the development of COVID-19 drugs and vaccines, Celltrion’s monoclonal antibody becomes the first therapeutic for the disease to be officially approved in South Korea.
Webinar Recording: Coronavirus Pharma Industry Impact In China, Korea And Japan
Join Jung Won Shin, Brian Yang and Ian Haydock in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series, COVID-19: Lessons Learned And A Path Forward.
How Was Korea Different In Handling COVID-19 Situation?
South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.